New statewide coalition calls on Albany to pass S.9289/A.10401 and close the transportation gap leaving students experiencing homelessness, foster care, and IEP placements without...
BEIJING, June 2, 2026 /PRNewswire/ -- Amap, Alibaba's location-based services platform, and the Singapore Tourism Board (STB) today signed a Memorandum of Understanding in...
Jon Keyser Appointed Interim Chief Executive OfficerMESA, Ariz., June 1, 2026 /PRNewswire/ -- Verra Mobility Corporation (NASDAQ: VRRM), a leading provider of smart mobility...
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Gemini Space Station, Inc. ("Gemini"), a global crypto platform, today announced that it has publicly filed a...
DALLAS, Aug. 15, 2025 /PRNewswire/ -- The Taiwan Excellence Pavilion made a dynamic debut at Taiwan Expo USA 2025 in Dallas, showcasing more than 60...
Wenge Invests in Cherrypicks to Jointly Drive China's AI Go-Global Strategy and Elevate Hong Kong's AI Ecosystem
HONG KONG, Aug. 15, 2025 /PRNewswire/ -- NetDragon...
Wenge Invests in Cherrypicks to Jointly Drive China's AI Go-Global Strategy and Elevate Hong Kong's AI Ecosystem
HONG KONG, Aug. 15, 2025 /PRNewswire/ -- NetDragon...
ZURICH, 15 août 2025 (GLOBE NEWSWIRE) -- L’EAACI a lancé sa Antibiotic Allergy Awareness Campaign (Campagne de sensibilisation aux allergies aux antibiotiques) à l’occasion de son Congrès 2025 à Glasgow. Cette initiative marque le début d’un effort mondial visant à lutter contre les erreurs d’étiquetage et son lien avec la résistance aux antimicrobiens (RAM).